Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHBP | P24387 | 1/20 | 0.67 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.67 |
| ▸ | HPGD | P15428 | 1/20 | 0.66 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.66 |
| ▸ | CA12 | O43570 | 2/20 | 0.57 |
| ▸ | CA2 | P00918 | 2/20 | 0.57 |
| ▸ | CA9 | Q16790 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.54 |
| ▸ | MAPT | P10636 | 5/20 | 0.54 |
| ▸ | MEN1 | O00255 | 5/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
| ▸ | DDX3X | O00571 | 1/20 | 0.54 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4540927 | 0.90 | MEN1 (0.55) | CRHBPCRHR2HPGDL3MBTL1CA12 | |
| SCHEMBL11932409 | 0.87 | CRHBP (0.60) | CRHBPCRHR2HPGDL3MBTL1CA12 | |
| SCHEMBL12768025 | 0.87 | CRHBP (0.76) | CRHBPCRHR2HPGDL3MBTL1CA12 | |
| SCHEMBL16430541 | 0.87 | CRHBP (0.57) | CRHBPCRHR2HPGDL3MBTL1CA2 | |
| SCHEMBL7897512 | 0.84 | CRHBP (0.68) | CRHBPCRHR2HPGDL3MBTL1CA12 | |
| SCHEMBL20657419 | 0.84 | HSD17B2 (0.53) | CRHBPCRHR2HPGDL3MBTL1CA12 | |
| SCHEMBL21893366 | 0.84 | CA2 (0.62) | CRHBPCRHR2HPGDL3MBTL1CA12 | |
| SCHEMBL28821820 | 0.83 | HPGD (0.70) | CRHBPCRHR2HPGDL3MBTL1CA12 | |
| SCHEMBL4536549 | 0.82 | ACLY (0.65) | CRHBPCRHR2HPGDL3MBTL1KMT2A | |
| SCHEMBL25330587 | 0.82 | CA2 (0.49) | CRHBPCRHR2HPGDL3MBTL1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1651595-A2 | UBIQUITIN LIGASE INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2006-05-03 | — | — | EP | claimed |
| WO-2005007621-A2 | UBIQUITIN LIGASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2005-01-27 | — | — | WO | claimed |
| US-20120172375-A1 | COMPOUNDS AND METHODS OF PROMOTING OLIGODENDROCYTE PRECURSOR DIFFERENTIATION | THE CLEVELAND CLINIC FOUNDATION | 2012-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172375-A1 | COMPOUNDS AND METHODS OF PROMOTING OLIGODENDROCYTE PRECURSOR DIFFERENTIATION | DCX, CHAT, GMFG | CRHBP 4163/4885CRHR2 4482/4885HPGD 778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.